Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02525939 · ClinicalTrials.gov registry record · Phase 3
Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS
A Phase 3 study, sponsored by DalCor Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 6,147
- Enrollment target
NCT02525939: Completed Phase 3 study, sponsored by DalCor Pharmaceuticals.
NCT02525939 is a Phase 3 study that has completed, run by DalCor Pharmaceuticals. The registered enrollment target is 6,147 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (696% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02525939, a Phase 3 study, has completed, sponsored by DalCor Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 6,147 participants
- Enrollment target
Study Summary
A placebo-controlled, randomized, double-blind, parallel group, phase III multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile. Subjects will provide informed consent before any study-specific procedures are performed. Subject enrollment may begin in the hospital and will continue following release from the hospital. Screening procedures may be performed at the time of the index ACS event or anytime thereafter, with the condition that randomization must occur within the mandated window (4-12 weeks after the index event). Subjects will be assessed based on their medical history. Those who are likely to qualify will undergo Genotype Assay testing to evaluate genetic determination for the presence of AA genotype.
Primary Outcome
All efficacy endpoints were adjudicated by an independent clinical endpoint committee (CEC). The primary efficacy endpoint was the time from randomization to the first occurrence of any component of the composite endpoint, which included death from cardiovascular causes, resuscitated cardiac arrest, non-fatal myocardial infarction, or non-fatal stroke, as positively adjudicated by the CEC.
Interventions
- DRUG Placebo
- DRUG dalcetrapib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,147 participants |
| Start Date | 2016-04 |
| Est. Completion | 2021-10 |
| Phase | Phase 3 |
What the finished NCT02525939 record still lists
NCT02525939 is an interventional study that assigns participants to a tested intervention. Its 6,147 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (696% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02525939 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02525939 about?
NCT02525939 is a clinical study titled "Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS". A placebo-controlled, randomized, double-blind, parallel group, phase III multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile. Subjects will provide informed consent before any study-specific procedures are performed. Subject enrollment may begin in t...
What is the current status of trial NCT02525939?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 6,147 participants. The study started on 2016-04. Estimated completion is 2021-10.
What interventions are being tested in trial NCT02525939?
The interventions under investigation include: Placebo (DRUG), dalcetrapib (DRUG).
Who is sponsoring clinical trial NCT02525939?
This trial is sponsored by DalCor Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02525939's enrollment target sits among peer trials
6,147 36th of 2000 higher than 1,965 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04774159 · 6,150 participants · Phase 3
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
- NCT06304168 · 6,150 participants
Validation of DNA Methylation Markers for Universal and Site-specific Guided Cancer Detection, VANGUARD Study
- NCT07049861 · 6,200 participants · NA
Advancing Biopsychosocial Care Training Initiative
- NCT07166861 · 6,080 participants · NA
Annual Wellness Visits vs GRACE-augmented Annual Wellness Visits For Older Adults With High Needs - Phase 2
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia